3.63 USD
-0.32 (-8.1%)
We assign a fundamental rating of 3 out of 10 to BGMSP. BGMSP was compared to 525 industry peers in the Biotechnology industry. The financial health of BGMSP is average, but there are quite some concerns on its profitability. BGMSP is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- BGMSP had negative earnings in the past year.
- In the past year BGMSP has reported a negative cash flow from operations.
- BGMSP had negative earnings in each of the past 5 years.
- In the past 5 years BGMSP always reported negative operating cash flow.
1.2 Ratios
- The Return On Assets of BGMSP (-85.49%) is worse than 70.29% of its industry peers.
- BGMSP has a Return On Equity (-98.28%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -85.49% | ||
| ROE | -98.28% | ||
| ROIC | N/A |
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for BGMSP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- BGMSP does not have a ROIC to compare to the WACC, probably because it is not profitable.
- BGMSP has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for BGMSP has been increased compared to 5 years ago.
- BGMSP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of -69.09, we must say that BGMSP is in the distress zone and has some risk of bankruptcy.
- BGMSP has a Altman-Z score of -69.09. This is amonst the worse of the industry: BGMSP underperforms 92.38% of its industry peers.
- BGMSP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -69.09 |
ROIC/WACCN/A
WACC8.88%
2.3 Liquidity
- A Current Ratio of 6.43 indicates that BGMSP has no problem at all paying its short term obligations.
- With a decent Current ratio value of 6.43, BGMSP is doing good in the industry, outperforming 65.71% of the companies in the same industry.
- BGMSP has a Quick Ratio of 5.07. This indicates that BGMSP is financially healthy and has no problem in meeting its short term obligations.
- BGMSP has a Quick ratio (5.07) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.43 | ||
| Quick Ratio | 5.07 |
3. Growth
3.1 Past
- BGMSP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.34%, which is quite impressive.
- Looking at the last year, BGMSP shows a quite strong growth in Revenue. The Revenue has grown by 9.46% in the last year.
EPS 1Y (TTM)96.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.97%
Revenue 1Y (TTM)9.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%710%
3.2 Future
- Based on estimates for the next years, BGMSP will show a very strong growth in Earnings Per Share. The EPS will grow by 57.16% on average per year.
- BGMSP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 1049.89% yearly.
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5YN/A
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for BGMSP. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BGMSP. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- BGMSP's earnings are expected to grow with 57.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.4%
EPS Next 3Y57.16%
5. Dividend
5.1 Amount
- BGMSP has a Yearly Dividend Yield of 16.53%, which is a nice return.
- In the last 3 months the price of BGMSP has falen by -35.04%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
- Compared to an average industry Dividend Yield of 1.18, BGMSP pays a better dividend. On top of this BGMSP pays more dividend than 99.81% of the companies listed in the same industry.
- BGMSP's Dividend Yield is rather good when compared to the S&P500 average which is at 1.85.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 16.53% |
5.2 History
- BGMSP has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)N/A
Div Incr YearsN/A
Div Non Decr YearsN/A
5.3 Sustainability
DPN/A
EPS Next 2Y19.4%
EPS Next 3Y57.16%
BIO GREEN MED SOLUTION - BGMS 6 PERP
NASDAQ:BGMSP (1/15/2026, 8:00:01 PM)
3.63
-0.32 (-8.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10
Earnings (Next)03-31 2026-03-31/amc
Inst Owners0.02%
Inst Owner ChangeN/A
Ins Owners62.28%
Ins Owner ChangeN/A
Market Cap17.79M
Revenue(TTM)81.00K
Net Income(TTM)-6.97M
Analysts43.33
Price TargetN/A
Short Float %0.02%
Short Ratio0.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 16.53% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-Date01-22 2026-01-22 (0.15)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)58.82%
Min Revenue beat(2)-100%
Max Revenue beat(2)217.65%
Revenue beat(4)1
Avg Revenue beat(4)-20.59%
Min Revenue beat(4)-100%
Max Revenue beat(4)217.65%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 219.59 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.51 | ||
| P/tB | 3.22 | ||
| EV/EBITDA | N/A |
EPS(TTM)-80.13
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.24
OCFYN/A
SpS0.02
BVpS1.45
TBVpS1.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -85.49% | ||
| ROE | -98.28% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.43 | ||
| Quick Ratio | 5.07 | ||
| Altman-Z | -69.09 |
F-Score5
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.97%
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5YN/A
Revenue 1Y (TTM)9.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%710%
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5YN/A
EBIT growth 1Y40.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y64.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.9%
OCF growth 3YN/A
OCF growth 5YN/A
BIO GREEN MED SOLUTION - BGMS 6 PERP / BGMSP FAQ
What is the fundamental rating for BGMSP stock?
ChartMill assigns a fundamental rating of 3 / 10 to BGMSP.
Can you provide the valuation status for BIO GREEN MED SOLUTION - BGMS 6 PERP?
ChartMill assigns a valuation rating of 1 / 10 to BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP). This can be considered as Overvalued.
What is the profitability of BGMSP stock?
BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) has a profitability rating of 0 / 10.
What is the expected EPS growth for BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) stock?
The Earnings per Share (EPS) of BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) is expected to grow by 39.49% in the next year.